pharmaceutics

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 6.9

an Open Access Journal by MDPI

Delivery of Oligonucleotide Therapeutics

Guest Editors:

Dr. Domenica Musumeci
Department of Chemical Sciences, University of Naples Federico II, 80126 Naples, Italy

Dr. Ettore Napolitano
Department of Chemical Sciences, University of Naples Federico II, 80126 Naples, Italy

Dr. Anna Di Porzio
Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy

Deadline for manuscript submissions:
10 June 2024

Message from the Guest Editors

Dear Colleagues,

Oligonucleotide therapeutics (OTs) are synthetic DNA or RNA strands with the potential to treat a wide range of diseases. Until now, fifteen FDA-approved oligonucleotide drugs have been released on the market, with many other OTs being investigated.

OTs are promising candidates in the pharmaceutical context. Nevertheless, one of the greatest challenges in oligonucleotide therapy is the delivery of the active substances to the site of action, mainly due to their unfavorable pharmacokinetic profile and nuclease degradation.

To overcome these issues, many strategies have been reported in the literature, ranging from chemical modifications of the DNA/RNA backbone to bioconjugation or encapsulation in nanocarriers.

The continuous progress in this field is gradually unlocking the true potential of oligonucleotide-based therapeutics, opening new perspectives and expanding the range of possible applications.

Authors are invited to submit original papers, communications and reviews regarding the delivery of oligonucleotide therapeutics.

Dr. Domenica Musumeci
Dr. Ettore Napolitano
Dr. Anna Di Porzio
Guest Editors

mdpi.com/si/194666

Special Issue

pharmaceutics

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 6.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
𝕏@MDPIpharma